Prospective QSAR-Based Prediction Models with Pharmacophore Studies of Oxadiazole-Substituted $$\alpha$$ α -Isopropoxy Phenylpropanoic Acids with Dual Activators of PPAR $$\alpha$$ α and PPAR $$\gamma$$ γ

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Interdisciplinary Sciences Computational Life Sciences

• Publication date

  2014-09-02

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s12539-015-0009-yPMID 26178333
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic algorithms

  2018cited by this paper
• 3D QSAR, pharmacophore indentification studies on series of 1-(2-ethoxyethyl)-1H-pyrazolo [4,3-d]pyrimidines as phosphodiesterase V inhibitors

  2015cited by this paper
• Thiazolidinediones in Type 2 Diabetes Mellitus

  2012cited by this paper
• The next generation of PPAR drugs: do we have the tools to find them?

  2007cited by this paper
• PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.

  2007cited by this paper
• Three-Dimensional QSAR Using the k-Nearest Neighbor Method and Its Interpretation

  2006cited by this paper
• Incretin Mimetics as Emerging Treatments for Type 2 Diabetes

  2005cited by this paper
• Therapeutic roles of peroxisome proliferator-activated receptor agonists.

  2005cited by this paper
• (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.

  2005cited by this paper
• Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus.

  2005cited by this paper
• Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection

  2004cited by this paper
• Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.

  2004cited by this paper
• Regulation of Muscle Fiber Type and Running Endurance by PPARδ

  2004cited by this paper
• Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

  2003cited by this paper
• An Introduction to Chemoinformatics

  2003cited by this paper
• Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation.

  2003cited by this paper
• Revealing the cost of Type II diabetes in Europe

  2002cited by this paper
• Predictive QSAR modeling based on diversity sampling of experimental datasets for the training and test set selection

  2002cited by this paper
• Revealing the cost of Type II diabetes in Europe.

  2002cited by this paper
• Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic Activity

  2002cited by this paper
• Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.

  2002cited by this paper
• An Alignment-Independent Versatile Structure Descriptor for QSAR and QSPR Based on the Distribution of Molecular Features

  2002cited by this paper
• Novel 5-substituted 2,4-thiazolidinedione and 2,4-oxazolidinedione derivatives as insulin sensitizers with antidiabetic activities.

  2002cited by this paper
• Genetic disruption of PPARdelta decreases the tumorigenicity of human colon cancer cells.

  2001cited by this paper
• Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARalpha, PPARgamma, and PPARdelta.

  2001cited by this paper
• (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity.

  2001cited by this paper
• Identification of a series of oxadiazole-substituted α-isopropoxy phenylpropanoic acids with activity on PPARα, PPARγ, and PPARδ

  2001cited by this paper
• Current therapies and emerging targets for the treatment of diabetes.

  2001cited by this paper
• A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport

  2001cited by this paper
• Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells

  2001cited by this paper
• Novel Variable Selection Quantitative Structure-Property Relationship Approach Based on the k-Nearest-Neighbor Principle

  2000cited by this paper
• Roles of PPARs in health and disease

  2000cited by this paper
• New therapies in diabetes – thiazolidinediones

  2000cited by this paper
• Peroxisome Proliferator-activated Receptor β Regulates Acyl-CoA Synthetase 2 in Reaggregated Rat Brain Cell Cultures*

  1999cited by this paper
• Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl-containing thiazolidinediones.

  1999cited by this paper
• A peroxisome proliferator-activated receptor gamma ligand inhibits adipocyte differentiation.

  1999cited by this paper
• GA Strategy for Variable Selection in QSAR Studies: Enhancement of Comparative Molecular Binding Energy Analysis by GA‐Based PLS Method

  1999cited by this paper
• A peroxisome proliferator-activated receptor g ligand inhibits adipocyte differentiation

  1999cited by this paper
• PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.

  1998cited by this paper
• N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 2. Structure-activity relationship and optimization of the phenyl alkyl ether moiety.

  1998cited by this paper
• Global Burden of Diabetes, 1995–2025: Prevalence, numerical estimates, and projections

  1998cited by this paper
• Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents.

  1998cited by this paper
• A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.

  1998cited by this paper
• Peroxisome proliferator-activated receptor gamma and the control of adipogenesis.

  1997cited by this paper
• The Rising Global Burden of Diabetes and its Complications: Estimates and Projections to the Year 2010

  1997cited by this paper
• The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

  1996cited by this paper
• Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.

  1996cited by this paper
• The structure - Activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones

  1996cited by this paper
• Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology.

  1996cited by this paper
• Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94

  1996cited by this paper
• Non thiazolidinedione antihyperglycaemic agents. 1: α-Heteroatom substituted β-phenylpropanoic acids

  1996cited by this paper
• Comparative docking studies on ligand binding to the multispecific antibodies IgE-La2 and IgE-Lb4

  1996cited by this paper
• On genetic algorithms

  1995cited by this paper
• The RXR heterodimers and orphan receptors.

  1995cited by this paper
• An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ) (*)

  1995cited by this paper
• An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma).

  1995cited by this paper
• Benzyloxazolidine-2,4-diones as potent hypoglycemic agents.

  1991cited by this paper
• Validation of the general purpose tripos 5.2 force field

  1989cited by this paper
• Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins.

  1988cited by this paper
• Studies on antidiabetic agents. II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]thiazolidine-2,4-dione (ADD-3878) and its derivatives.

  1982cited by this paper
• ITERATIVE PARTIAL EQUALIZATION OF ORBITAL ELECTRONEGATIVITY – A RAPID ACCESS TO ATOMIC CHARGES

  1980cited by this paper

• Structural insights and molecular profiling of a large set of diverse compounds targeting PPARγ: from comprehensive cheminformatics approach to tool development

  2025cites this paper
• Molecular Modeling Approach to Study the PPARγ-Ligand Interactions.

  2019cites this paper
• Molecular determinants of PPARγ partial agonism and related in silico/in vivo studies of natural saponins as potential type 2 diabetes modulators.

  2018cites this paper
• Molecular docking, 3D-QSAR and structural optimization on imidazo-pyridine derivatives dually targeting AT1 and PPARγ

  2017cites this paper
• Molecular Modeling Studies of Thiophenyl C-Aryl Glucoside SGLT2 Inhibitors as Potential Antidiabetic Agents

  2014cites this paper